RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma

Feifei Chen1, Jin Bai, Wang Li

  • 1Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, Jiangsu, China.

Plos One
|March 5, 2013
PubMed

Insights

RUNX3 (runt-related transcription factor-3) is often decreased in renal cell carcinoma (RCC). Restoring RUNX3 inhibits RCC cell migration, invasion, and angiogenesis, suggesting its potential as a therapeutic target for kidney cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • RUNX3 (runt-related transcription factor-3) is a known tumor suppressor with antitumor activity.
  • The role of RUNX3 in human renal cell carcinoma (RCC) remains largely unexplored.

Purpose of the Study:

  • To investigate the clinical significance of RUNX3 expression in RCC patients.
  • To elucidate the functional role of RUNX3 in RCC cell migration, invasion, and angiogenesis.

Main Methods:

  • Immunohistochemistry on 75 RCC tissues and paired non-cancerous tissues using tissue microarray (TMA).
  • Assays for cell migration, invasion, proliferation, and endothelial tube formation.
  • Gelatin zymography, Western blot, ELISA to assess MMP-9 and VEGF levels.

Main Results:

  • RUNX3 expression was significantly decreased in RCC tissues and correlated with tumor size, invasion depth, and TNM stage.
  • Restoration of RUNX3 suppressed RCC cell migration and invasion.
  • Overexpression of RUNX3 inhibited endothelial cell proliferation, tube formation, MMP-9 activity, and VEGF expression/secretion.

Conclusions:

  • Decreased RUNX3 expression is linked to RCC progression.
  • RUNX3 restoration inhibits RCC cell migration, invasion, and angiogenesis, highlighting its potential therapeutic role in kidney cancer.